NYU Langone Health has been selected as 1 of 23 institutions to join the American Association for Thoracic Surgery’s Thoracic Surgery Oncology Group (TSOG). A North American clinical trials network for thoracic surgery, TSOG aims to improve the understanding of thoracic oncologic diseases and enhance the care of patients.

“Over the last few years, Perlmutter Cancer Center has recruited some of the top surgical, medical, pulmonary, and radiation oncologists in the country,” says Harvey I. Pass, MD, director of general thoracic surgery and surgical chief of thoracic oncology at NYU Langone’s Perlmutter Cancer Center. “Combined with our recent designation as a Comprehensive Cancer Center by the National Cancer Institute, selection as a member of the TSOG highlights Perlmutter Cancer Center’s position as a major lung cancer center in the United States.”

Established in 2017, the TSOG actively recruits patients to relevant thoracic surgeon–led oncologic clinical trials. The focus is on phase 1 and 2 studies, window-of-opportunity trials with correlative analyses, intraoperative imaging studies, relevant registry studies, and multidisciplinary study designs.

Among the founding cancer centers of the TSOG are Brigham and Women’s Hospital, Duke University, the Mayo Clinic, the University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Centre Hospitalier de l’Université de Montréal, the University of Pittsburgh, the University of Toronto, and Washington University in St. Louis.

To be considered for the TSOG, institutions must be high-volume centers for thoracic oncologic procedures with an emphasis on lung cancer, esophageal cancer, and other thoracic malignancies and show evidence of site-specific financial sustainability and existing infrastructure for completion of clinical trials with active participation of thoracic surgeons with expertise in oncologic clinical trials and a history of robust accrual.

Selection to join the TSOG is the latest accolade Perlmutter Cancer Center’s Thoracic Medical Oncology Program has received this year. Its NYU Langone Cardiothoracic Surgery Associates recently earned a distinguished three-out-of-three-star rating from The Society of Thoracic Surgeons for its care of patients with lung cancer who have a lobectomy.

Being a member of the TSOG will help improve partnerships in the translational and clinical trial component of Perlmutter Cancer Center’s research, which is led by Kwok-Kin Wong, MD, PhD, director of the Division of Hematology and Medical Oncology and the Anne Murnick Cogan and David H. Cogan Professor of Oncology in the Department of Medicine.

“Joining the TSOG is another way to strengthen Perlmutter Cancer Center’s lung cancer program by participating in cutting-edge trials with the leading thoracic surgery programs in the country,” Dr. Pass says.

Media Inquiries

Jeffrey Molter
Phone: 212-263-9423
jeffrey.molter@nyulangone.org